person · Reporting owner

Meltz Mark A

Disclosed activity across 3 companies

Tapewire entity: 66896
SEC CIK: 0001771329

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Lyell Immunopharma, Inc.LYEL · Entity 5757	General Counsel	February 10, 2026	February 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Lyell Immunopharma, Inc.

Report date February 10, 2026 · Filed February 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.71 · Expires 2036-02-09	Direct	50,000	Reported balance After 2026-02-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-10 · Grant · Acquired 50,000 · Balance 50,000 F1: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Audentes Therapeutics, Inc.

Report date January 15, 2020 · Filed January 15, 2020

Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-01-15 transaction · row 1 1 source row Row 1 · 2020-01-15 · Other · Disposed 32,705 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest. F3: Includes 28,000 shares of Company common stock issuable upon the settlement of restricted stock units.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.26 · Expires 2029-03-28	Direct	0	Reported balance After 2020-01-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-15 · Disposition to issuer · Disposed 104,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest.

F3: Includes 28,000 shares of Company common stock issuable upon the settlement of restricted stock units.

F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Kinnate Biopharma Inc.

Report date April 03, 2024 · Filed April 05, 2024

Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-04-03 transaction · row 1 1 source row Row 1 · 2024-04-03 · Disposition to issuer · Disposed 27,578 · Balance 0 F1: Includes 15,625 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. F2: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2030-04-02	Direct	Reported balance After 2024-04-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-04-03 · Disposition to issuer · Disposed 384,508 · Balance 0 F3: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.63 · Expires 2030-08-18	Direct	Reported balance After 2024-04-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-04-03 · Disposition to issuer · Disposed 121,503 · Balance 0 F4: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.38 · Expires 2031-02-12	Direct	Reported balance After 2024-04-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-04-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.03 · Expires 2032-02-11	Direct	Reported balance After 2024-04-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-04-03 · Disposition to issuer · Disposed 135,000 · Balance 0 F4: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2033-02-10	Direct	Reported balance After 2024-04-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-04-03 · Disposition to issuer · Disposed 215,000 · Balance 0 F4: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 15,625 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.

F2: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.

F3: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option.

F4: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 10, 2026 Filed Feb 12, 2026 02:01 UTC	Lyell Immunopharma, Inc. LYEL · Entity 5757	GrantOption (right to buy) · Derivative	50,000	$0.00 Strike: $23.71	$0.00	Disclosure SEC source: 0001771329-26-000001 · form4-02122026_020247.xml · derivative · entry 1 Meltz Mark A · CIK 0001771329 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-02-09 F1 · derivative.exercise_date: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date. Read SEC document
June 09, 2025 Filed Jun 11, 2025 21:47 UTC	Lyell Immunopharma, Inc. LYEL · Entity 5757	GrantOption (right to buy) · Derivative	100,000	$0.00 Strike: $12.47	$0.00	Disclosure SEC source: 0001415889-25-016729 · form4-06112025_090608.xml · derivative · entry 1 Meltz Mark A · CIK 0001771329 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-06-08 F1 · derivative.exercise_date: 25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date. Read SEC document
April 03, 2024 Filed Apr 5, 2024 16:55 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Disposition to issuerStock Option (right to buy) · Derivative	215,000	Not disclosed Strike: $6.78	Not disclosed	Disclosure SEC source: 0001415889-24-010424 · form4-04052024_040402.xml · derivative · entry 6 Meltz Mark A · CIK 0001771329 · COO GENERAL COUNSEL SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 215,000 shares Expires 2033-02-10 F4 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F4 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document
April 03, 2024 Filed Apr 5, 2024 16:55 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Disposition to issuerStock Option (right to buy) · Derivative	135,000	Not disclosed Strike: $10.03	Not disclosed	Disclosure SEC source: 0001415889-24-010424 · form4-04052024_040402.xml · derivative · entry 5 Meltz Mark A · CIK 0001771329 · COO GENERAL COUNSEL SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,000 shares Expires 2032-02-11 F4 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F4 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document
April 03, 2024 Filed Apr 5, 2024 16:55 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Disposition to issuerStock Option (right to buy) · Derivative	100,000	Not disclosed Strike: $35.38	Not disclosed	Disclosure SEC source: 0001415889-24-010424 · form4-04052024_040402.xml · derivative · entry 4 Meltz Mark A · CIK 0001771329 · COO GENERAL COUNSEL SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-02-12 F4 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F4 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document
April 03, 2024 Filed Apr 5, 2024 16:55 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Disposition to issuerStock Option (right to buy) · Derivative	121,503	Not disclosed Strike: $5.63	Not disclosed	Disclosure SEC source: 0001415889-24-010424 · form4-04052024_040402.xml · derivative · entry 3 Meltz Mark A · CIK 0001771329 · COO GENERAL COUNSEL SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,503 shares Expires 2030-08-18 F4 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F4 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document
April 03, 2024 Filed Apr 5, 2024 16:55 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Disposition to issuerStock Option (right to buy) · Derivative	384,508	Not disclosed Strike: $2.57	Not disclosed	Disclosure SEC source: 0001415889-24-010424 · form4-04052024_040402.xml · derivative · entry 2 Meltz Mark A · CIK 0001771329 · COO GENERAL COUNSEL SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 384,508 shares Expires 2030-04-02 F3 · price: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option. F3 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option. Read SEC document
April 03, 2024 Filed Apr 5, 2024 16:55 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Disposition to issuerCommon Stock	27,578	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-010424 · form4-04052024_040402.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · COO GENERAL COUNSEL SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 15,625 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. F2 · price: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR. Read SEC document
March 01, 2024 Filed Mar 5, 2024 17:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Tax withholdingCommon Stock	558	$2.59	$1,445.22	Disclosure SEC source: 0001415889-24-006753 · form4-03052024_050301.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · COO GENERAL COUNSEL SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,578 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of restricted stock units ("RSUs") granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 15,625 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document
December 01, 2023 Filed Dec 5, 2023 17:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Tax withholdingCommon Stock	541	$2.25	$1,217.25	Disclosure SEC source: 0001209191-23-057454 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,136 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of restricted stock units ("RSUs") granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 17,188 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document
September 01, 2023 Filed Sep 6, 2023 17:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Tax withholdingCommon Stock	541	$2.35	$1,271.35	Disclosure SEC source: 0001209191-23-048426 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,677 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 18,750 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 17:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Tax withholdingCommon Stock	541	$4.30	$2,326.30	Disclosure SEC source: 0001209191-23-034444 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,218 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 20,313 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. F3 · balance_after: Includes 2,473 shares acquired under the Issuers Employee Stock Purchase Plan in May 2023. Read SEC document
March 01, 2023 Filed Mar 3, 2023 17:57 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Tax withholdingCommon Stock	638	$5.21	$3,323.98	Disclosure SEC source: 0001209191-23-015873 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,286 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 21,875 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document
February 10, 2023 Filed Feb 14, 2023 17:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantEmployee Stock Option (right to buy) · Derivative	215,000	$0.00 Strike: $6.78	$0.00	Disclosure SEC source: 0001209191-23-009206 · doc4.xml · derivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2033-02-10 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document
December 01, 2022 Filed Dec 2, 2022 20:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	Tax withholdingCommon Stock	541	$7.75	$4,192.75	Disclosure SEC source: 0001209191-22-059513 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,924 F1 · balance_after: Includes 23,438 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document
September 01, 2022 Filed Sep 2, 2022 17:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-048525 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,465 F1 · kind: The Issuer granted RSUs to the Reporting Person. Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. F2 · balance_after: Includes 1,729 shares acquired under the Issuer's Employee Stock Purchase Plan (the "Plan") in May 2021, 595 shares acquired under the Plan in November 2021, and 1,141 shares acquired under the Plan in May 2022. Read SEC document
February 11, 2022 Filed Feb 15, 2022 16:01 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantEmployee Stock Option (right to buy) · Derivative	135,000	$0.00 Strike: $10.03	$0.00	Disclosure SEC source: 0001209191-22-009742 · doc4.xml · derivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-02-11 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document
February 12, 2021 Filed Feb 16, 2021 18:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantEmployee Stock Option (right to buy) · Derivative	100,000	$0.00 Strike: $35.38	$0.00	Disclosure SEC source: 0001209191-21-010902 · doc4.xml · derivative · entry 1 Meltz Mark A · CIK 0001771329 · COO General Counsel Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-12 F1 · derivative.exercise_date: The Option vests and becomes exercisable over time at the following rate: 1/48th of the total number of shares subject to the Option shall vest each month in equal installments starting on March 1, 2021. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:32 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	104,000	Not disclosed Strike: $37.26	Not disclosed	Disclosure SEC source: 0001209191-20-003431 · doc4.xml · derivative · entry 2 Meltz Mark A · CIK 0001771329 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,000 shares Expires 2029-03-28 F4 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:32 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	OtherCommon Stock	32,705	$60.00	$1,962,300.00	Disclosure SEC source: 0001209191-20-003431 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · kind: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest. F3 · shares: Includes 28,000 shares of Company common stock issuable upon the settlement of restricted stock units. Read SEC document
December 12, 2019 Filed Dec 16, 2019 18:04 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Tax withholdingCommon Stock	4,628	$59.37	$274,764.36	Disclosure SEC source: 0001209191-19-060729 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,705 F1 · security: On December 10, 2019, the Compensation Committee of the Issuer's Board of Directors approved the accelerated vesting and settlement of restricted stock units granted on March 28, 2019 in order to mitigate the potential adverse tax consequences of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended. F2 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document
March 28, 2019 Filed Apr 1, 2019 17:54 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	104,000	$0.00 Strike: $37.26	$0.00	Disclosure SEC source: 0001209191-19-022056 · doc4.xml · derivative · entry 2 Meltz Mark A · CIK 0001771329 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 104,000 shares Expires 2029-03-28 F2 · derivative.exercise_date: The options will vest as to 25% of the total shares on March 28, 2020, and then 2.0833% of the shares monthly thereafter, such that the option is fully vested on March 28, 2023, subject to the Reporting Person's provision of service to the issuer on each vesting date. Read SEC document
March 28, 2019 Filed Apr 1, 2019 17:54 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantCommon Stock	37,333	$0.00	$0.00	Disclosure SEC source: 0001209191-19-022056 · doc4.xml · nonDerivative · entry 1 Meltz Mark A · CIK 0001771329 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,333 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 25% of the award on March 5, 2020, and then 6.25% of the RSUs will vest quarterly on June 5, September 5, December 5, and March 5 such that the RSUs are fully vested on March 5, 2023, subject to the Reporting Person's provision of services to the issuer on each vesting date. Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.